Neuroprotective effects of niosomes loaded with thymoquinone in the cerebral ischemia model of male Wistar rats.

Autor: Hatami Nemati S; Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran., Bigdeli MR; Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran; Institute for Cognitive and Brain Science, Shahid Beheshti University, Tehran, Iran. Electronic address: mr_bigdeli@sbu.ac.ir., Mortazavi Moghadam F; Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. Electronic address: fatimamortazavi@ut.ac.ir., Sharifi K; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jazyk: angličtina
Zdroj: Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2023 Feb; Vol. 48, pp. 102637. Date of Electronic Publication: 2022 Dec 20.
DOI: 10.1016/j.nano.2022.102637
Abstrakt: The complex stroke pathophysiology, like oxidative stress and inflammatory reactions, causes substantially challenged in stroke treatment. Thymoquinone (TQ) is attributed to pharmacological actions like antioxidant and anti-inflammation. Thymoquinone is chemically hydrophobic, which causes poor solubility and bioavailability. To overcome this challenge Thymoquinone niosome was applied in this in-vivo study. The results demonstrated a significant reduction in rats treated with Thymoquinone niosome compared to free Thymoquinone and control groups (SOD), (TAC), and (GPX) activities were increased in the TQN group compared to the MCAO control group. The decrease in (MDA) level was seen in the Thymoquinone niosome group compared to the MCAO control group. The inflammation factors expression rates of IL-IB, IL-6, TNFα in I/R Thymoquinone niosome group were decreased. This study indicated that Thymoquinone niosome might be utilized as a promising novel carrier to improve Thymoquinone bioavailability and therapeutic effect in treating cerebral I/R injury.
Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interest.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: